Clinical Trials on Orthomyxoviridae Infections

Total 56704 results

GlaxoSmithKline

Completed

Immunogenicity and Safety Study to Evaluate Different Formulations of GSK Biologicals' Influenza Vaccine GSK576389A

Influenza

Germany, Sweden, United Kingdom, Netherlands
GlaxoSmithKline

Completed

Evaluation of Safety and Immunogenicity of GSK Bio's Influenza Vaccine GSK576389A After Repeated Vaccination in Elderly Adults

Influenza

Belgium
GlaxoSmithKline

Completed

Trial to Evaluate the Efficacy of GSK Biologicals' Influenza Vaccine GSK2186877A in Adults 65 Year of Age and Older

Influenza

France, Germany, United States, Taiwan, Estonia, Poland, Canada, Romania, Russian Federation, Belgium, United Kingdom, Netherlands, Norway, Mexico, Czechia
Stanford University
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

B-cell Immunity to Influenza (SLVP017)- Year 5, 2013

Influenza
Stanford University
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

B-cell Immunity to Influenza (SLVP017) - Years 2 (2010) & 3 (2011)

Influenza
Seqirus

Completed

A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 5 Through 17 Years of Age

Influenza, Human

United States
Seqirus

Completed

A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine

Influenza

United States
GlaxoSmithKline

Completed

Safety, Immunogenicity, and Relative Efficacy of H1N1 Vaccines in Adults Aged 18 Years and Older

Influenza

United States, Canada
Sanofi Pasteur, a Sanofi Company

Completed

Comparative Study of Immunogenicity and Safety of Flu-ID Vaccine Versus Flu-IM Vaccine

Influenza

Belgium, France
GlaxoSmithKline

Completed

Study to Evaluate Reactogenicity and Immunogenicity of Revaccination With Adjuvanted Influenza Vaccine in Elderly

Influenza

Belgium
Sanofi Pasteur, a Sanofi Company

Completed

A Study of the Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Subjects Aged 65 Years and Older

Influenza

United States
GlaxoSmithKline

Completed

Safety and Immunogenicity of H1N1 Vaccines in Adults Aged 18 Years and Older

Influenza

United States, Canada
University of Michigan
Sanofi Pasteur, a Sanofi Company

Completed

Comparative Study of Influenza Vaccines in Adults, FLUVACS-year 4 (FLUVACS)

Influenza

United States
Tan Tock Seng Hospital
National Healthcare Group, Singapore

Completed

Tropical Influenza Control Strategies for the Elderly (TROPICS1)

Influenza, Human

Singapore
SK Chemicals Co., Ltd.

Completed

Immunogenicity and Safety of Quadrivalent Influenza Vaccine in Children Aged 6~35 Months

Influenza, Human

Korea, Republic of
Protein Sciences Corporation

Completed

Trial to Evaluate the Immunogenicity and Safety of Panblok® (H7 rHA) in Healthy Adults Aged 18 and Older (PSC26)

Influenza

United States
GlaxoSmithKline

Completed

Evaluate Reactogenicity & Immunogenicity of an Influenza Pandemic Candidate Vaccine (GSK1562902A) in Primed Adults

Influenza

Belgium
UMN Pharma Inc.

Completed

Phase-3 Study of ASP7374, Cell-culture-derived Influenza Vaccine

Influenza

Japan
Mahidol University

Completed

Effect of Drinking Fermented Milk on Immune Response

Influenza
Stanford University
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) Year 2, 2010

Influenza
National Institute of Allergy and Infectious Diseases...

Completed

Alternative Oseltamivir Dosing Strategies

Influenza

United States
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine(s) GSK3206641A and GSK3206640A Administered in Adults 18 to 64 Years of Age

Influenza

United States, Canada
National Institute of Allergy and Infectious Diseases...

Completed

Evaluation of Anti-Hemagglutinin (Anti-HA) Antibodies as Protection From the Flu in Healthy People

Influenza

United States
Novartis Vaccines

Completed

A Study to Evaluate the Safety of Two Influenza Vaccines in Children and Adolescents 3 to <18 Years of Age at Risk for Influenza-Related Complications

Influenza

Italy, Spain
Stanford University
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Pilot Study in Young Adults to Examine the Kinetics of Changes in the B-cell Repertoire Following TIV Immunization (SLVP023)

Influenza
University of Colorado, Denver
University of Alabama at Birmingham; All India Institute of Medical Sciences... and other collaborators

Completed

Influenza Immunization of Children in India

Influenza

India
GlaxoSmithKline

Completed

A Study to Demonstrate the Efficacy of GSK Biologicals' Influenza Vaccine in Adults

Influenza

Finland, Czech Republic
Seqirus

Completed

A Study to Evaluate the Immunogenicity and Safety of bioCSL Quadrivalent Influenza Vaccine (QIV) in Adults Aged 18 Years and Above.

Influenza, Human

United States
Trial Management Group Inc.
Hoffmann-La Roche

Completed

Effect of Oseltamivir on Cognitive Function in Subjects With Influenza (FOCUS)

Influenza

Canada
Novartis
Novartis Vaccines

Completed

Second Extension Study to Evaluate Safety and Tolerability of Influenza Vaccines in Adults and Elderly, and to Evaluate Immunogenicity and Concomitant Vaccination With Pneumococcal Vaccine in a Subgroup

Influenza

Poland
University of Rochester
National Institutes of Health (NIH); Dartmouth-Hitchcock Medical Center

Completed

Effect of Age and Prior Immunity to Response to Seasonal Influenza Vaccines in Children

Influenza

United States
Novartis Vaccines

Completed

Safety and Immunogenicity of 2 Commercially Available Influenza Vaccines in Children

Influenza

Finland
Novartis Vaccines

Completed

Immunogenicity and Safety of V70P5 Revaccination Subjects

Influenza

Finland
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of the 2015-2016 Formulation of Fluzone® Quadrivalent (Influenza Vaccine) Among Healthy Children

Influenza

United States
GlaxoSmithKline

Completed

A Phase III, Open-Label, Single-Dose Study to Evaluate the Safety and Immunogenicity of Fluviral® Vaccine

Influenza

Canada
GlaxoSmithKline

Terminated

Study to Evaluate the Immune Response and the Safety of Fluarix TM/ Influsplit SSW® 2010/2011 or Pandemrix TM

Influenza

Germany
GlaxoSmithKline

Completed

Incidence of Influenza, Downstream Complications of Influenza & Hospitalizations in Elderly Vaccinated With Fluarix™

Influenza

Australia, Brazil
International Centre for Infectious Diseases, Canada

Completed

Comparison of Epidemiology and Clinical Outcomes of Influenza A & B Cases in Manitoba, Canada

Influenza

Canada
GlaxoSmithKline

Completed

Study to Evaluate the Safety and Immunogenicity of Fluarix™ 2006/2007 in Adults Aged 18 Years or Above

Influenza

Germany
Protein Sciences Corporation

Completed

Safety, Reactogenicity and Immunogenicity of Flublok Quadrivalent (Recombinant Influenza Vaccine,Seasonal Formulation)

Influenza

United States
GlaxoSmithKline

Completed

Immuno & Reacto of TF Trivalent Influenza Split Vaccine 2003/04 or of Std Formulation Influsplit SSW®/Fluarix™ 2003/04

Influenza

Germany
Hoffmann-La Roche

Completed

A Study on Emergence of Resistance With Oseltamivir (Tamiflu) in Participants With Seasonal Influenza

Influenza

Brazil
The University of Hong Kong

Unknown

Improving Influenza Vaccination Rates in Nurses Through Text Message Reminders : a RCT

Influenza

China
Biota Scientific Management Pty Ltd
Department of Health and Human Services

Terminated

Safety & Pharmacokinetics Study of Inhaled Laninamivir Octanoate TwinCaps® Dry Powder Inhaler in Children With Influenza (FROSTY)

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Evaluation of Responses to Fluzone® in Infants ≥ 6 Months of Age Who Did or Did Not Receive Fluzone® at 2 Months of Age

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of Influenza Vaccine Revaccination in Healthy Adults Previously Vaccinated With Fluzone ID or Fluzone IM

Influenza

United States, Puerto Rico
Sanofi Pasteur, a Sanofi Company

Completed

Phase IV Trial to Collect Safety Data and Sera for Immunogenicity Testing in Healthy Children Given Fluzone® Vaccine

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Trial to Describe the Safety and Immunogenicity of Fluzone®

Influenza

United States
National Institute of Allergy and Infectious Diseases...
The Emmes Company, LLC

Completed

Seasonal Influenza DNA Vaccine Prime With Trivalent Inactivated Vaccine (TIV) Boost Compared to TIV Alone

Influenza

United States
The First Affiliated Hospital of Guangzhou Medical...

Unknown

Lingdancao Granules in the Treatment of Seasonal Influenza

Influenza

3

Subscribe